Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
Oncolytics announced more than 20 patients pre-identified for REO 033 colorectal cancer trial and scheduled Type D meeting with the FDA.
Oncolytics announced more than 20 patients pre-identified for REO 033 colorectal cancer trial and scheduled Type D meeting with the FDA.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.